RxDoctor Payments Data

Lea Ochs

Nurse Practitioner · Pittsburgh, PANPI 1861742587

Payments from drug & device makers

$3,676in general payments, 2019–2025

Across 75 payments — averaging $49.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • AstraZeneca$984
  • Otsuka America Pharmaceutical, Inc.$446
  • Acadia Pharmaceuticals Inc$441
  • Lilly USA, LLC$279
  • Neurocrine Biosciences, Inc.$214
  • plus $173 from 3 others

What the payments were for

  • Grants$87624%
  • Food & beverage$2,68873%
  • Education$1113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,676 in reported general payments places this provider in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$134,339
Medicare patients
469
Services billed
1,497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate25$88,540
EliquisApixaban88$31,314
TrulicityDulaglutide21$12,224
MyrbetriqMirabegron39$9,209
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,004
JardianceEmpagliflozin25$7,935
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,519
Rosuvastatin Calcium35$1,978
Escitalopram Oxalate47$1,805
Tramadol Hcl126$1,645
Levothyroxine Sodium111$1,562
Pregabalin36$1,379
Oxycodone Hcl85$1,187
Mirtazapine38$1,146
Lorazepam122$1,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$214$88,54025 claims
Lilly USA, LLCTrulicity, Olanzapine$279$12,62648 claims
GSKTrelegy Ellipta$14$9,00412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →